194
|
1124
|
7n5hA |
Cryo-em structure of broadly neutralizing antibody 2-36 in complex with prefusion sars-cov-2 spike glycoprotein |
44
|
157
|
7mfgB |
Cryo-em structure of the vrc310 clinical trial, vaccine-elicited, human antibody 310-030-1d06 fab in complex with an h1 nc99 ha trimer |
18
|
128
|
7n5hE |
Cryo-em structure of broadly neutralizing antibody 2-36 in complex with prefusion sars-cov-2 spike glycoprotein |
47
|
322
|
7mfgA |
Cryo-em structure of the vrc310 clinical trial, vaccine-elicited, human antibody 310-030-1d06 fab in complex with an h1 nc99 ha trimer |
15
|
120
|
7mfgE |
Cryo-em structure of the vrc310 clinical trial, vaccine-elicited, human antibody 310-030-1d06 fab in complex with an h1 nc99 ha trimer |
12
|
108
|
7mfgF |
Cryo-em structure of the vrc310 clinical trial, vaccine-elicited, human antibody 310-030-1d06 fab in complex with an h1 nc99 ha trimer |
18
|
107
|
7n5hF |
Cryo-em structure of broadly neutralizing antibody 2-36 in complex with prefusion sars-cov-2 spike glycoprotein |
45
|
223
|
7s3nH |
Sars-cov-2 s stem helix peptide bound to fab22 |
3
|
10
|
7s3nA |
Sars-cov-2 s stem helix peptide bound to fab22 |
42
|
223
|
7s3mH |
Mers-cov s stem helix peptide bound to fab22 |
4
|
14
|
7s3mA |
Mers-cov s stem helix peptide bound to fab22 |
52
|
214
|
7s3nL |
Sars-cov-2 s stem helix peptide bound to fab22 |
48
|
217
|
7s3mL |
Mers-cov s stem helix peptide bound to fab22 |
208
|
1117
|
7s0cA |
Structure of the sars-cov-2 s 6p trimer in complex with neutralizing antibody n-612-017 |
187
|
1130
|
7s0dA |
Structure of the sars-cov-2 s 6p trimer in complex with neutralizing antibody n-612-014 |
30
|
223
|
7s0eH |
Structure of the sars-cov-2 s1 subunit in complex with antibody n-612-004 |
19
|
121
|
7rr0B |
Sars-cov-2 receptor binding domain bound to fab pdi 222 |
76
|
686
|
7s0eA |
Structure of the sars-cov-2 s1 subunit in complex with antibody n-612-004 |
28
|
214
|
7s0eL |
Structure of the sars-cov-2 s1 subunit in complex with antibody n-612-004 |
33
|
214
|
7s0cL |
Structure of the sars-cov-2 s 6p trimer in complex with neutralizing antibody n-612-017 |
47
|
222
|
7s0bA |
Structure of the sars-cov-2 rbd in complex with neutralizing antibody n-612-056 |
32
|
194
|
7rr0A |
Sars-cov-2 receptor binding domain bound to fab pdi 222 |
36
|
225
|
7s0cH |
Structure of the sars-cov-2 s 6p trimer in complex with neutralizing antibody n-612-017 |
31
|
214
|
7s0dL |
Structure of the sars-cov-2 s 6p trimer in complex with neutralizing antibody n-612-014 |
38
|
199
|
7s0bE |
Structure of the sars-cov-2 rbd in complex with neutralizing antibody n-612-056 |
18
|
107
|
7rr0C |
Sars-cov-2 receptor binding domain bound to fab pdi 222 |
20
|
223
|
7s0dH |
Structure of the sars-cov-2 s 6p trimer in complex with neutralizing antibody n-612-014 |
44
|
213
|
7s0bB |
Structure of the sars-cov-2 rbd in complex with neutralizing antibody n-612-056 |
31
|
209
|
7n64L |
Sars-cov-2 spike (2p) in complex with g32r7 fab (rbd and ntd local reconstruction) |
47
|
216
|
7n4jL |
Crystal structure of sars-cov-2 receptor binding domain in complex with neutralizing human antibody wrair-2173. |
34
|
277
|
7n62A |
Sars-cov-2 spike (2p) in complex with c12c9 fab (ntd local reconstruction) |
45
|
199
|
7n4iC |
Crystal structure of sars-cov-2 receptor binding domain in complex with neutralizing human antibody wrair-2057. |
14
|
117
|
7n9aA |
Potent neutralizing nanobodies resist convergent circulating variants of sars-cov-2 by targeting novel and conserved epitopes-covs rbd with nb21 |
30
|
277
|
7n64A |
Sars-cov-2 spike (2p) in complex with g32r7 fab (rbd and ntd local reconstruction) |
44
|
223
|
7n62H |
Sars-cov-2 spike (2p) in complex with c12c9 fab (ntd local reconstruction) |
30
|
230
|
7n64H |
Sars-cov-2 spike (2p) in complex with g32r7 fab (rbd and ntd local reconstruction) |
37
|
221
|
7n4iH |
Crystal structure of sars-cov-2 receptor binding domain in complex with neutralizing human antibody wrair-2057. |
44
|
202
|
7n4jA |
Crystal structure of sars-cov-2 receptor binding domain in complex with neutralizing human antibody wrair-2173. |
203
|
1120
|
7n9eA |
Potent neutralizing nanobodies resist convergent circulating variants of sars-cov-2 by targeting novel and conserved epitopes-covs with nb34 |
25
|
195
|
7n9aE |
Potent neutralizing nanobodies resist convergent circulating variants of sars-cov-2 by targeting novel and conserved epitopes-covs rbd with nb21 |
11
|
126
|
7n9cD |
Potent neutralizing nanobodies resist convergent circulating variants of sars-cov-2 by targeting novel and conserved epitopes-covs with nb95 |
45
|
212
|
7n4iL |
Crystal structure of sars-cov-2 receptor binding domain in complex with neutralizing human antibody wrair-2057. |
174
|
1121
|
7n9bA |
Potent neutralizing nanobodies resist convergent circulating variants of sars-cov-2 by targeting novel and conserved epitopes-covs with nb21 |
16
|
117
|
7n9bD |
Potent neutralizing nanobodies resist convergent circulating variants of sars-cov-2 by targeting novel and conserved epitopes-covs with nb21 |
17
|
125
|
7n9eD |
Potent neutralizing nanobodies resist convergent circulating variants of sars-cov-2 by targeting novel and conserved epitopes-covs with nb34 |
41
|
212
|
7n62L |
Sars-cov-2 spike (2p) in complex with c12c9 fab (ntd local reconstruction) |
45
|
234
|
7n4jH |
Crystal structure of sars-cov-2 receptor binding domain in complex with neutralizing human antibody wrair-2173. |
24
|
229
|
7mwwE |
Structure of hepatitis c virus envelope full-length glycoprotein 2 (ee2) from j6 genotype |
17
|
233
|
7mwxC |
Structure of the core ectodomain of the hepatitis c virus envelope glycoprotein 2 with tamarin cd81 |
48
|
218
|
7mwwL |
Structure of hepatitis c virus envelope full-length glycoprotein 2 (ee2) from j6 genotype |